Showing results (81-90 of 222) with videos related to

Sort By:
Pageof 23
Frontiers in Toxicology|July 25, 2025
25 years of research and regulation: Is nanotechnology safe to commercialize?Kirsten Rasmussen, Phil Sayre, Andrej Kobe, et al.
Toxicology Letters|November 1, 2013
Dexamethasone differentially regulates Bcl-2 family proteins in human proliferative chondrocytes: role of pro-apoptotic BidFarasat Zaman, Dionisios Chrysis, Kirsten Huntjens, et al.
Medical Oncology (Northwood, London, England)|February 19, 2008
Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesisDaniel Tesfa, Tobias Gelius, Birgitta Sander, et al.
Journal of Leukocyte Biology|August 15, 2018
JAGN1 is required for fungal killing in neutrophil extracellular traps: Implications for severe congenital neutropeniaAvinash Khandagale, Beatrice Lazzaretto, Göran Carlsson, et al.
Arthritis and Rheumatism|May 12, 2011
Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infectionsDaniel Tesfa, Sofia Ajeganova, Hans Hägglund, et al.
Biochemical and Biophysical Research Communications|October 10, 2007
VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic miceChengyun Zheng, Mattias K Sköld, Jian Li, et al.
Nanomedicine (London, England)|September 3, 2020
No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19Georgia Wilson Jones, Marco P Monopoli, Luisa Campagnolo, et al.
Seminars in Immunology|September 5, 2017
Nanoparticles and innate immunity: new perspectives on host defenceDiana Boraschi, Paola Italiani, Roberto Palomba, et al.
Scientific Reports|January 19, 2019
INSIdE NANO: a systems biology framework to contextualize the mechanism-of-action of engineered nanomaterialsAngela Serra, Ivica Letunic, Vittorio Fortino, et al.
Pageof 23